POST Online Media Lite Edition



 

Merck solves Vioxx class action, will pay $830 million

Staff writer |
Merck has reached an agreement with plaintiffs to resolve In re Merck & Co. Securities Litigation, a multi-district class action lawsuit pending in New Jersey federal court.

Article continues below






$680
million will be recorded as a charge in Q4 2015.
The settlement class consists of persons who purchased Merck securities during the period from May 21, 1999, through October 29, 2004, inclusive, and who seek to recover damages under the federal securities laws for certain Merck statements regarding Vioxx.

Under the agreement, Merck will pay $830 million to resolve the settlement class members’ claims, plus an additional amount for approved attorneys’ fees and expenses.

After available funds under certain insurance policies, Merck’s cash payment for the settlement and fees will be approximately $680 million, for which the company will record a charge in the fourth quarter of 2015, which will be excluded from non-GAAP results. The agreement is subject to court approval.

The settlement does not constitute any admission by Merck or any of the individual defendants of any liability or wrongdoing.

Merck still faces previously disclosed individual securities lawsuits related to Vioxx.


What to read next

Gilead Sciences to pay Merck $200 million for infringing two patents
Merck to acquire Afferent Pharmaceuticals in $1.25 billion deal
Merck and Pfizer together against type 2 diabetes